about
Towards a new combination therapy for tuberculosis with next generation benzothiazinonesOrosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulationResidual antimalarials in malaria patients from Tanzania--implications on drug efficacy assessment and spread of parasite resistanceDeterminants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapyA Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected PatientsOseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.Validation of an HPLC method for the determination of urinary and plasma levels of N1-methylnicotinamide, an endogenous marker of renal cationic transport and plasma flow.Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.Photodynamic therapy selectively enhances liposomal doxorubicin uptake in sarcoma tumors to rodent lungs.Antibiotic stability over six weeks in aqueous solution at body temperature with and without heat treatment that mimics the curing of bone cementPopulation pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania.Low-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis ModelPhotodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density.Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, andA simple, robust and rapid approach to detect carbapenemases in Gram-negative isolates by MALDI-TOF mass spectrometry: validation with triple quadripole tandem mass spectrometry, microarray and PCR.Prospective determination of plasma imipenem concentrations in critically ill children.Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infectionSofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report.Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.Treatment of pleural malignancies by photo-induction combined to systemic chemotherapy: Proof of concept on rodent lung tumors and feasibility study on porcine chest cavities.Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individualsAn inhibitor of HIV-1 protease modulates constitutive eIF2α dephosphorylation to trigger a specific integrated stress response.Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumoursMultiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.Privacy-preserving genomic testing in the clinic: a model using HIV treatment.Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection.Is Penicillin Plus Gentamicin Synergistic against Clinical Group B Streptococcus isolates?: An In vitro Study.Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature.Label-free detection of tobramycin in serum by transmission-localized surface plasmon resonance.Shotgun ecotoxicoproteomics of Daphnia pulex: biochemical effects of the anticancer drug tamoxifen.Therapeutic drug monitoring of targeted anticancer therapy.Residual antimalarial concentrations before treatment in patients with malaria from Cambodia: indication of drug pressure.
P50
Q27681604-DB501F4B-B5AB-41D9-B0A6-DD4583F4D646Q28266466-2678C124-6845-4D5E-9EE8-63610C45BCE1Q28472222-023FF0B1-B085-4D57-B8B0-ABC46FFC0407Q28478666-405ACF36-5FEF-4DFA-A89E-94B54C91AB1AQ28546535-A09D2790-8550-4D8B-AB6F-FA5F3B57E1B8Q30394541-7185533E-E46E-484B-A7DB-51396D04910CQ31994847-5FC99A72-9EBC-4694-AD1C-D08CB4872637Q33269667-C3391C2E-75FD-40FA-939E-CA02E2A98DDDQ33522300-28C56084-88AB-41F7-9EC6-2968B6D304FBQ33618068-735F5079-316F-4930-A25B-1516304E4410Q33759744-A7C81F06-8706-4310-A7CC-5A229F25323EQ34058351-887D155C-D082-4447-AFC7-14ED99237B41Q34092162-371243B5-F0BC-4188-97F4-D776B2A1E5D7Q34169468-3AD330EE-2452-431B-8A18-EFDE98B2A138Q34290041-754BF93B-0CD1-4B50-923C-C502122AAF15Q34309603-8E481EE1-D5E4-45D3-BDD0-3051FBFA9BB6Q34424853-9B06E88A-CAE9-4F04-9EC6-80B98D863EE4Q34721638-425FA260-7652-4A5E-AF4D-076D8AA21256Q35127808-4452235A-7406-46E3-80C9-8F1809D511F7Q35228316-64BF0562-3FE6-4EDC-9BF7-783F88773D0CQ35635830-F1705A1A-5A58-49B2-875C-05FCBDCE7730Q35790604-9583455B-897F-4CFE-AD0D-FABAF41DF393Q36018556-D49FF39D-DFB0-49DD-8406-00541E85D00CQ36483172-E6B2226A-F39C-4C4C-9CBD-B0CF1DFCFB8CQ36558437-DFC3CD35-B03A-4C4B-9342-9C77088AD2D7Q36729934-13625018-1AEC-43CA-9D8A-CF4C917DD194Q36969893-E8E068AF-9098-4134-95D2-F9D4CDFBABFBQ37038270-2B18001F-4DA3-4059-BE0C-7FEB6C478E9AQ37176937-F8723293-8737-4EB9-8992-B66F3DC9D5ABQ37334935-E8205116-7DA8-4FC3-93BC-169E6E04B0B8Q37356030-AD0A05A7-BF63-4B4A-AF8B-D211EBE8A788Q37489345-805FDD6A-0C09-404F-855A-C71B6D9A3BA4Q37538683-5E20EA72-D376-4634-9C44-CF9C10790E8CQ37570464-B8A9C83C-1E6B-4A20-B24D-737B2BE2CA80Q37866298-DBDB61E6-F974-4913-90E9-12DF2B13304EQ38211997-984A814F-6839-414D-908F-8E8E4B69CD06Q38300212-6E910397-BFA0-464F-B25E-2F49A2109211Q38421644-0E1FF31D-D420-46F4-94E9-F274208D7571Q38579278-728577D9-1DC4-401E-8154-E262CA594EC2Q39069809-1713572D-4442-44EB-AE94-15539E595F22
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Laurent Arthur Decosterd
@ast
Laurent Arthur Decosterd
@en
Laurent Arthur Decosterd
@es
Laurent Arthur Decosterd
@nl
type
label
Laurent Arthur Decosterd
@ast
Laurent Arthur Decosterd
@en
Laurent Arthur Decosterd
@es
Laurent Arthur Decosterd
@nl
prefLabel
Laurent Arthur Decosterd
@ast
Laurent Arthur Decosterd
@en
Laurent Arthur Decosterd
@es
Laurent Arthur Decosterd
@nl
P108
P106
P31
P496
0000-0002-9840-1325